Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,756 across all filing types
Latest filing 2025-05-13 Call Transcript
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 85% confidence The document is a letter addressed to the stock exchange (BSE Limited) announcing a post quarterly financial result conference call scheduled for May 20, 2025, to discuss the financial performance for the quarter and year ended March 31, 2025. It provides dial-in details and a registration link for the call. The document does not contain any financial data or analysis itself, nor does it include a transcript or detailed presentation. It is an announcement of an upcoming event (conference call) related to financial results, not the results or report itself. Therefore, it fits best under the category of Call Transcript (CT) announcements or related. However, since this is only an announcement of the call and not the transcript, and given the available categories, the closest and most appropriate classification is Call Transcript (CT) as it pertains to the conference call event about financial results.
2025-05-13 English
Board Meeting — Financial Results/Dividend/Fund Raising/Other business matters
Board/Management Information Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) informing about the date of an upcoming Board Meeting. It mentions that the Board will consider approving the Audited Financial Results for the fiscal year ended 31-Mar-25, recommendation of final dividend, and potential fundraising via equity shares or convertible bonds. The document is a notification of a future board meeting and agenda items, not the actual financial results or reports. It is short (1845 characters) and serves as an intimation under SEBI regulations. Therefore, it is an announcement related to board meeting scheduling and agenda, which fits the category of Board/Management Information (MANG).
2025-05-13 English
Torrent Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 ,inter alia, to consider and approve the Audited Financial ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) informing about the date of an upcoming Board Meeting scheduled for 20-May-2025. The letter states that the Board will consider approving the Audited Financial Results for the year ended 31-Mar-2025, recommend a final dividend, and consider resolutions for raising funds through equity shares or convertible bonds. This is a typical announcement of a Board Meeting date and agenda items under SEBI regulations. The document does not contain any financial data or results itself, nor is it a report or transcript. It is an intimation or notice of a Board Meeting. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2025-05-13 English
Updates
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) regarding the cessation of a director of the company, Dr Maurice Chagnaud, due to completion of his tenure. It references compliance with SEBI Listing Regulations and provides details about the director's cessation. There is no financial data, no report attached or referenced as being published, and the content focuses solely on management change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-05-11 English
Intimation of cessation of Director of the Company
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) regarding the cessation of a director of the company, Dr Maurice Chagnaud, who has completed his tenure as an Independent Director. It references compliance with SEBI Listing Regulations and provides details about the director's cessation. There is no financial data, earnings information, or report attached or referenced as being published. The content clearly relates to a change in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and focused solely on this announcement, confirming it is not a full report or other filing type.
2025-05-11 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2025-04-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.